API CAS 1110813-31-4 Dacomitinib Material Dacomitinib Powder Dacomitinib CAS NO.1110813-31-4

Advantages:
 
Hubei XinRunde Chemical Co., Ltd is a renowned pharmaceutical manufacturer. We can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. Never stop striving to offer our best service is our philosophy. We have Flexible and Untraceable payment terms. As a leading manufacture, our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries.

1. Quality.Every batch of steroid powders have tobetested by our QC(quality control) before they are allowed to sell.

2. Delivery We have stock, so we can delivery quickly at the very day when receive the payment. Within 24 hours after receiving the payment Lead time 4 or 7 days.

3. Discreet package Safelyand Professionally Disguised Package Guaranteed. For your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.

4. Warm after-sale service Any of your question would be solved for the first as soon as possible.

Product Description:
Item Name:  Dacomitinib
CAS NO.:1110813-31-4
Apparence:White Powder
Place of Origin: China (Mainland)
Assay:No less than 99%
Packaging Details:100g,1kg/bag, 25kg/drum

Uses: Dacomitinib (PF299804), which name is (E)-N-[4-(3-chloro-4-fluoroanilino)-7- methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide, is a potent, orally available, highly selective, irreversible small-molecule tyrosine kinase inhibitor (TKI) of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. It is most effective against EGFR with IC50 of 6 nM. It is highly effective against NSCLCs carrying EGFR or ERBB2 mutant (anti-Gefitinib) and EGFR T790M mutant.

What is Dacomitinib
It is a drug used to treat non-small cell lung cancer. It is a selective and irreversible inhibitor of EGFR. Dacomitinib has undergone a number of phase III clinical trials.

Dacomitinib  is approved to treat:
Dacotinib is suitable for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R missense mutation